Virus-like particles: The new frontier of vaccines for animal viral infections

Veterinary Immunology and Immunopathology

Volumn 148, Issue 3-4, 2012, Pages 211-225

  Crisci, Elisa ^a   Bárcena, Juan ^b   Montoya, María ^a,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

^c IRTA   (Spain)

Author keywords

Animal vaccines; Vaccine vectors; Virus like particles (VLPs)

Indexed keywords

B LYMPHOCYTE ANTIGEN; CIRCOFLEX; CIRCOVIRUS VACCINE; NEWCASTLE DISEASE VACCINE; PATTERN RECOGNITION RECEPTOR; PORCILIS PCV; PORCINE CIRCOVIRUS TYPE 2 VACCINE; PORCINE PARVOVIRUS VIRUS LIKE PARTICLE VACCINE; PROTEIN VP1; PROTEIN VP2; PROTEIN VP7; RECOMBINANT HEPATITIS B VACCINE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE; WART VIRUS VACCINE;

ANIMAL DISEASE; CALICIVIRUS; CELLULAR IMMUNITY; CIRCOVIRIDAE INFECTION; CIRCOVIRUS; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; EQUINE RHINITIS A VIRUS; ERBOVIRUS; FOOT AND MOUTH DISEASE VIRUS; GYROVIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTIOUS BURSAL DISEASE VIRUS; NEWCASTLE DISEASE; NONHUMAN; PLANT VIRUS; REOVIRUS; REOVIRUS INFECTION; REVIEW; ROTAVIRUS; SYSTEMATIC REVIEW; VACCINATION; VIRUS INFECTION; VIRUS LIKE AGENT;

ANIMALIA;

EID: 84865033019     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2012.04.026     Document Type: Review

References (167)

1. Abrams C.C., King A.M., Belsham G.J. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J. Gen. Virol. 1995, 76(Pt 12):3089-3098.
2. Albrecht P., Ennis F.A., Saltzman E.J., Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 1977, 91:715-718.
3. Almanza H., Cubillos C., Angulo I., Mateos F., Caston J.R., van der Poel W.H., Vinje J., Barcena J., Mena I. Self-assembly of the recombinant capsid protein of a swine norovirus into virus-like particles and evaluation of monoclonal antibodies cross-reactive with a human strain from genogroup II. J. Clin. Microbiol. 2008, 46:3971-3979.
4. Angulo E., Barcena J. Towards a unique and transmissible vaccine against myxomatosis and rabbit haemorrhagic disease for rabbit populations. Wildl. Res. 2007, 34:567-577.
5. Antonis A.F., Bruschke C.J., Rueda P., Maranga L., Casal J.I., Vela C., Hilgers L.A., Belt P.B., Weerdmeester K., Carrondo M.J., Langeveld J.P. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 2006, 24:5481-5490.
6. Azad I.S., Shekhar M.S., Thirunavukkarasu A.R., Poornima M., Kailasam M., Rajan J.J., Ali S.A., Abraham M., Ravichandran P. Nodavirus infection causes mortalities in hatchery produced larvae of Lates calcarifer: first report from India. Dis. Aquat. Organ. 2005, 63:113-118.
7. Bachmann M.F., Jennings G.T. Virus-Like particles: combining innate and adaptive immunity for effective vaccination. Novel Vaccination Strategies 2004, 415-432. Wiley-VCH Verlag GmbH & Co. H.E.K. Stefan (Ed.).
8. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010, 10:787-796.
9. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262:1448-1451.
10. Bachmann M.F., Zinkernagel R.M. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 1997, 15:235-270.
11. Bank-Wolf B.R., Konig M., Thiel H.J. Zoonotic aspects of infections with noroviruses and sapoviruses. Vet. Microbiol. 2010, 140:204-212.
12. Barcena J., Verdaguer N., Roca R., Morales M., Angulo I., Risco C., Carrascosa J.L., Torres J.M., Caston J.R. The coat protein of rabbit hemorrhagic disease virus contains a molecular switch at the N-terminal region facing the inner surface of the capsid. Virology 2004, 322:118-134.
13. Beesley K.M., Francis M.J., Clarke B.E., Beesley J.E., Dopping-Hepenstal P.J., Clare J.J., Brown F., Romanos M.A. Expression in yeast of amino-terminal peptide fusions to hepatitis B core antigen and their immunological properties. Biotechnology (N.Y.) 1990, 8:644-649.
14. Berg T.P. Acute infectious bursal disease in poultry: a review. Avian Pathol. 2000, 29:175-194.
15. Bertolotti-Ciarlet A., Ciarlet M., Crawford S.E., Conner M.E., Estes M.K. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 2003, 21:3885-3900.
16. Billinis C., Paschaleri-Papadopoulou E., Psychas V., Vlemmas J., Leontides S., Koumbati M., Kyriakis S.C., Papadopoulos O. Persistence of encephalomyocarditis virus (EMCV) infection in piglets. Vet. Microbiol. 1999, 70:171-177.
17. Bishop R.F. Natural history of human rotavirus infection. Arch. Virol. Suppl. 1996, 12:119-128.
18. Bragard C., Duncan G.H., Wesley S.V., Naidu R.A., Mayo M.A. Virus-like particles assemble in plants and bacteria expressing the coat protein gene of Indian peanut clump virus. J. Gen. Virol. 2000, 81:267-272.
19. Branco L.M., Grove J.N., Geske F.J., Boisen M.L., Muncy I.J., Magliato S.A., Henderson L.A., Schoepp R.J., Cashman K.A., Hensley L.E., Garry R.F. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol. J. 2010, 7:279.
20. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., Schiller J.T., Lowy D.R. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 1995, 69:3959-3963.
21. Brun A., Barcena J., Blanco E., Borrego B., Dory D., Escribano J.M., Le Gall-Recule G., Ortego J., Dixon L.K. Current strategies for subunit and genetic viral veterinary vaccine development. Virus Res. 2011, 157:1-12.
22. Buckland B.C. The process development challenge for a new vaccine. Nat. Med. 2005, 11:S16-S19.
23. Caballero S., Guix S., Ribes E., Bosch A., Pinto R.M. Structural requirements of astrovirus virus-like particles assembled in insect cells. J. Virol. 2004, 78:13285-13292.
24. Campo M.S. Vaccination against papillomavirus in cattle. Clin. Dermatol. 1997, 15:275-283.
25. Canizares M.C., Nicholson L., Lomonossoff G.P. Use of viral vectors for vaccine production in plants. Immunol. Cell Biol. 2005, 83:263-270.
26. Cao Y., Lu Z., Sun J., Bai X., Sun P., Bao H., Chen Y., Guo J., Li D., Liu X., Liu Z. Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs. Vet. Microbiol. 2009, 137:10-17.
27. Casal J.I. Use of the baculovirus expression system for the generation of virus-like particles. Biotechnol. Genet. Eng. Rev. 2001, 18:73-87.
28. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev. Vaccines 2007, 6:381-390.
29. Chackerian B., Lowy D.R., Schiller J.T. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2373-2378.
30. Charpilienne A., Nejmeddine M., Berois M., Parez N., Neumann E., Hewat E., Trugnan G., Cohen J. Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells. J. Biol. Chem. 2001, 276:29361-29367.
31. Christensen J., Alexandersen S., Bloch B., Aasted B., Uttenthal A. Production of mink enteritis parvovirus empty capsids by expression in a baculovirus vector system: a recombinant vaccine for mink enteritis parvovirus in mink. J. Gen. Virol. 1994, 75(Pt 1):149-155.
32. Clarke B.E., Newton S.E., Carroll A.R., Francis M.J., Appleyard G., Syred A.D., Highfield P.E., Rowlands D.J., Brown F. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 1987, 330:381-384.
33. Conner M.E., Crawford S.E., Barone C., Estes M.K. Rotavirus vaccine administered parenterally induces protective immunity. J. Virol. 1993, 67:6633-6641.
34. Conner M.E., Estes M.K. Virus-like particle vaccines. New Generation Vaccines 2004, 283-293. Informa Healthcare. M.M. Levine, J.B. Kaper, R. Rapuoli, M.A. Liu, M.F. Good (Eds.).
35. Conner M.E., Zarley C.D., Hu B., Parsons S., Drabinski D., Greiner S., Smith R., Jiang B., Corsaro B., Barniak V., Madore H.P., Crawford S., Estes M.K. Virus-like particles as a rotavirus subunit vaccine. J. Infect. Dis. 1996, 174(Suppl. 1):S88-S92.
36. Cooke B.D. Rabbit haemorrhagic disease: field epidemiology and the management of wild rabbit populations. Rev. Sci. Tech. 2002, 21:347-358.
37. Cox M.M. Recombinant protein vaccines produced in insect cells. Vaccine 2012, 30:1759-1766.
38. Coyne K.P., Jones B.R., Kipar A., Chantrey J., Porter C.J., Barber P.J., Dawson S., Gaskell R.M., Radford A.D. Lethal outbreak of disease associated with feline calicivirus infection in cats. Vet. Rec. 2006, 158:544-550.
39. Crisci E., Almanza H., Mena I., Cordoba L., Gomez-Casado E., Caston J.R., Fraile L., Barcena J., Montoya M. Chimeric calicivirus-like particles elicit protective anti-viral cytotoxic responses without adjuvant. Virology 2009, 387:303-312.
40. Crisci E., Fraile L., Moreno N., Blanco E., Cabezon R., Costa C., Mussa T., Baratelli M., Martinez-Orellana P., Ganges L., Martinez J., Barcena J., Montoya M. Chimeric calicivirus-like particles elicit specific immune responses in pigs. Vaccine 2012, 30:2427-2439.
41. D'Aoust M.A., Couture M.M., Charland N., Trepanier S., Landry N., Ors F., Vezina L.P. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 2010, 8:607-619.
42. Dalsgaard K., Uttenthal A., Jones T.D., Xu F., Merryweather A., Hamilton W.D., Langeveld J.P., Boshuizen R.S., Kamstrup S., Lomonossoff G.P., Porta C., Vela C., Casal J.I., Meloen R.H., Rodgers P.B. Plant-derived vaccine protects target animals against a viral disease. Nat. Biotechnol. 1997, 15:248-252.
43. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M.E., Koukavica I., Baz M., Abed Y., Savard C., Pare C., Lopez Macias C., Boivin G., Leclerc D. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26:3395-3403.
44. Di Martino B., Marsilio F., Roy P. Assembly of feline calicivirus-like particle and its immunogenicity. Vet. Microbiol. 2007, 120:173-178.
45. Douglas T., Young M. Viruses: making friends with old foes. Science 2006, 312:873-875.
46. El Mehdaoui S., Touze A., Laurent S., Sizaret P.Y., Rasschaert D., Coursaget P. Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16. J. Virol. 2000, 74:10332-10340.
47. Eriksson M., Andreasson K., Weidmann J., Lundberg K., Tegerstedt K., Dalianis T., Ramqvist T. Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor. PLoS ONE 2011, 6:e23828.
48. Fachinger V., Bischoff R., Jedidia S.B., Saalmuller A., Elbers K. The effect of vaccination against porcine circovirus type 2 in pigs suffering from porcine respiratory disease complex. Vaccine 2008, 26:1488-1499.
49. Fehr T., Skrastina D., Pumpens P., Zinkernagel R.M. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9477-9481.
50. Fernandez-Fernandez M.R., Martinez-Torrecuadrada J.L., Roncal F., Dominguez E., Garcia J.A. Identification of immunogenic hot spots within plum pox potyvirus capsid protein for efficient antigen presentation. J. Virol. 2002, 76:12646-12653.
51. Fernandez F.M., Conner M.E., Hodgins D.C., Parwani A.V., Nielsen P.R., Crawford S.E., Estes M.K., Saif L.J. Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from cows immunized with recombinant SA11 rotavirus core-like particle (CLP) or virus-like particle (VLP) vaccines. Vaccine 1998, 16:507-516.
52. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., McKenzie I.F., Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 2004, 173:3148-3154.
53. Flick R., Bouloy M. Rift valley fever virus. Curr. Mol. Med. 2005, 5:827-834.
54. Fort M., Sibila M., Allepuz A., Mateu E., Roerink F., Segales J. Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins. Vaccine 2008, 26:1063-1071.
55. Fort M., Sibila M., Perez-Martin E., Nofrarias M., Mateu E., Segales J. One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model. Vaccine 2009, 27:4031-4037.
56. Garcea R.L., Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr. Opin. Biotechnol. 2004, 15:513-517.
57. Garrone P., Fluckiger A.C., Mangeot P.E., Gauthier E., Dupeyrot-Lacas P., Mancip J., Cangialosi A., Du Chene I., LeGrand R., Mangeot I., Lavillette D., Bellier B., Cosset F.L., Tangy F., Klatzmann D., Dalba C. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 2011, 3:94ra71.
58. Gedvilaite A., Dorn D.C., Sasnauskas K., Pecher G., Bulavaite A., Lawatscheck R., Staniulis J., Dalianis T., Ramqvist T., Schonrich G., Raftery M.J., Ulrich R. Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. Virology 2006, 354:252-260.
59. Gelmetti D., Meroni A., Brocchi E., Koenen F., Cammarata G. Pathogenesis of encephalomyocarditis experimental infection in young piglets: a potential animal model to study viral myocarditis. Vet. Res. 2006, 37:15-23.
60. Goldmann C., Petry H., Frye S., Ast O., Ebitsch S., Jentsch K.D., Kaup F.J., Weber F., Trebst C., Nisslein T., Hunsmann G., Weber T., Luke W. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J. Virol. 1999, 73:4465-4469.
61. Grgacic E.V., Anderson D.A. Virus-like particles: passport to immune recognition. Methods 2006, 40:60-65.
62. Hainisch E.K., Brandt S., Shafti-Keramat S., Van den Hoven R., Kirnbauer R. Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses. Equine Vet. J. 2012, 44:107-111.
63. Han M.G., Cheetham S., Azevedo M., Thomas C., Saif L.J. Immune responses to bovine norovirus-like particles with various adjuvants and analysis of protection in gnotobiotic calves. Vaccine 2006, 24:317-326.
64. Haynes J.R. Influenza virus-like particle vaccines. Expert Rev. Vaccines 2009, 8:435-445.
65. Hervas-Stubbs S., Rueda P., Lopez L., Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J. Immunol. 2007, 178:2361-2369.
66. Istrate C., Hinkula J., Charpilienne A., Poncet D., Cohen J., Svensson L., Johansen K. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine 2008, 26:4594-4601.
67. Jagadish M.N., Edwards S.J., Hayden M.B., Grusovin J., Vandenberg K., Schoofs P., Hamilton R.C., Shukla D.D., Kalnins H., McNamara M., Haynes J., Nisbet I.T., Ward C.W., Pye D. Chimeric potyvirus-like particles as vaccine carriers. Intervirology 1996, 39:85-92.
68. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., Bachi T., Storni T., Jennings G., Pumpens P., Renner W.A., Bachmann M.F. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002, 20:3104-3112.
69. Jennings G.T., Bachmann M.F. The coming of age of virus-like particle vaccines. Biol. Chem. 2008, 389:521-536.
70. Jeoung H.Y., Lee W.H., Jeong W., Ko Y.J., Choi C.U., An D.J. Immune responses and expression of the virus-like particle antigen of the porcine encephalomyocarditis virus. Res. Vet. Sci. 2010, 89:295-300.
71. Jeoung H.Y., Lee W.H., Jeong W., Shin B.H., Choi H.W., Lee H.S., An D.J. Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig. Virol. J. 2011, 8:170.
72. Jiang B., Estes M.K., Barone C., Barniak V., O'Neal C.M., Ottaiano A., Madore H.P., Conner M.E. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 1999, 17:1005-1013.
73. Jin H., Xiao W., Xiao C., Yu Y., Kang Y., Du X., Wei X., Wang B. Protective immune responses against foot-and-mouth disease virus by vaccination with a DNA vaccine expressing virus-like particles. Viral Immunol. 2007, 20:429-440.
74. Johnson J.E., Chiu W. Structures of virus and virus-like particles. Curr. Opin. Struct. Biol. 2000, 10:229-235.
75. Ju H., Wei N., Wang Q., Wang C., Jing Z., Guo L., Liu D., Gao M., Ma B., Wang J. Goose parvovirus structural proteins expressed by recombinant baculoviruses self-assemble into virus-like particles with strong immunogenicity in goose. Biochem. Biophys. Res. Commun. 2011, 409:131-136.
76. Kang S.M., Pushko P., Bright R.A., Smith G., Compans R.W. Influenza virus-like particles as pandemic vaccines. Curr. Top. Microbiol. Immunol. 2009, 333:269-289.
77. Kang S.M., Song J.M., Quan F.S., Compans R.W. Influenza vaccines based on virus-like particles. Virus Res. 2009, 143:140-146.
78. Koch G., van Roozelaar D.J., Verschueren C.A., van der Eb A.J., Noteborn M.H. Immunogenic and protective properties of chicken anaemia virus proteins expressed by baculovirus. Vaccine 1995, 13:763-770.
79. Koo M., Bendahmane M., Lettieri G.A., Paoletti A.D., Lane T.E., Fitchen J.H., Buchmeier M.J., Beachy R.N. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7774-7779.
80. Kouskoff V., Lacaud G., Nemazee D. T cell-independent rescue of B lymphocytes from peripheral immune tolerance. Science 2000, 287:2501-2503.
81. Kratz P.A., Bottcher B., Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1915-1920.
82. Kumar S., Ochoa W., Singh P., Hsu C., Schneemann A., Manchester M., Olson M., Reddy V. Tomato bushy stunt virus (TBSV), a versatile platform for polyvalent display of antigenic epitopes and vaccine design. Virology 2009, 388:185-190.
83. Lacasse P., Denis J., Lapointe R., Leclerc D., Lamarre A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. J. Virol. 2008, 82:785-794.
84. Langeveld J.P., Brennan F.R., Martinez-Torrecuadrada J.L., Jones T.D., Boshuizen R.S., Vela C., Casal J.I., Kamstrup S., Dalsgaard K., Meloen R.H., Bendig M.M., Hamilton W.D. Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus. Vaccine 2001, 19:3661-3670.
85. Laurent S., Vautherot J.F., Madelaine M.F., Le Gall G., Rasschaert D. Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection. J. Virol. 1994, 68:6794-6798.
86. Le Gall-Recule G., Jestin V., Chagnaud P., Blanchard P., Jestin A. Expression of muscovy duck parvovirus capsid proteins (VP2 and VP3) in a baculovirus expression system and demonstration of immunity induced by the recombinant proteins. J. Gen. Virol. 1996, 77(Pt 9):2159-2163.
87. Lewis S.A., Morgan D.O., Grubman M.J. Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J. Virol. 1991, 65:6572-6580.
88. Li C., Liu F., Liang M., Zhang Q., Wang X., Wang T., Li J., Li D. Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice. Vaccine 2010, 28:4294-4300.
89. Li F., Drummer H.E., Ficorilli N., Studdert M.J., Crabb B.S. Identification of noncytopathic equine rhinovirus 1 as a cause of acute febrile respiratory disease in horses. J. Clin. Microbiol. 1997, 35:937-943.
90. Liu W., Hsu C.H., Chang C.Y., Chen H.H., Lin C.S. Immune response against grouper nervous necrosis virus by vaccination of virus-like particles. Vaccine 2006, 24:6282-6287.
91. Liu W.J., Liu X.S., Zhao K.N., Leggatt G.R., Frazer I.H. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology 2000, 273:374-382.
92. Liu Y.V., Massare M.J., Barnard D.L., Kort T., Nathan M., Wang L., Smith G. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 2011, 29:6606-6613.
93. Lopez-Macias C., Ferat-Osorio E., Tenorio-Calvo A., Isibasi A., Talavera J., Arteaga-Ruiz O., Arriaga-Pizano L., Hickman S.P., Allende M., Lenhard K., Pincus S., Connolly K., Raghunandan R., Smith G., Glenn G. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011, 29:7826-7834.
94. Lopez de Turiso J.A., Cortes E., Martinez C., Ruiz de Ybanez R., Simarro I., Vela C., Casal I. Recombinant vaccine for canine parvovirus in dogs. J. Virol. 1992, 66:2748-2753.
95. Ludwig C., Wagner R. Virus-like particles-universal molecular toolboxes. Curr. Opin. Biotechnol. 2007, 18:537-545.
96. Luque D., González J.M., Gómez-Blanco J., Marabini R., Chichón J., Mena I., Angulo I., Carrascosa J.L., Verdaguer N., Trus B.L., Bárcena J., Castón J.R. Epitope insertion at the N-terminal molecular switch of the rabbit hemorrhagic disease virus t=3 capsid protein leads to larger t=4 capsids. J. Virol. 2012, 86:6470-6480.
97. Lynch S.E., Gilkerson J.R., Symes S.J., Huang J.A., Tatarczuch L., Hartley C.A. Equine rhinitis A virus-like particle expressing DNA vaccine induces a virus neutralising immune response in mice. Virus Res. 2011, 158:294-297.
98. Maclachlan N.J., Drew C.P., Darpel K.E., Worwa G. The pathology and pathogenesis of bluetongue. J. Comp. Pathol. 2009, 141:1-16.
99. Marek M., van Oers M.M., Devaraj F.F., Vlak J.M., Merten O.W. Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals. Biotechnol. Bioeng. 2011, 108:1056-1067.
100. Martelli P., Ferrari L., Morganti M., De Angelis E., Bonilauri P., Guazzetti S., Caleffi A., Borghetti P. One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions. Vet. Microbiol. 2011, 149:339-351.
101. Martinez-Torrecuadrada J.L., Saubi N., Pages-Mante A., Caston J.R., Espuna E., Casal J.I. Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines. Vaccine 2003, 21:3342-3350.
102. Mateu M.G. Virus engineering: functionalization and stabilization. Protein Eng. Des. Sel. 2011, 24:53-63.
103. Mazeike E., Gedvilaite A., Blohm U. Induction of insert-specific immune response in mice by hamster polyomavirus VP1 derived virus-like particles carrying LCMV GP33 CTL epitope. Virus Res. 2012, 163:2-10.
104. McGinnes L.W., Pantua H., Laliberte J.P., Gravel K.A., Jain S., Morrison T.G. Assembly and biological and immunological properties of Newcastle disease virus-like particles. J. Virol. 2010, 84:4513-4523.
105. Meeusen E.N., Walker J., Peters A., Pastoret P.P., Jungersen G. Current status of veterinary vaccines. Clin. Microbiol. Rev. 2007, 20:489-510.
106. Mena J.A., Kamen A.A. Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Rev. Vaccines 2011, 10:1063-1081.
107. Middelberg A.P., Rivera-Hernandez T., Wibowo N., Lua L.H., Fan Y., Magor G., Chang C., Chuan Y.P., Good M.F., Batzloff M.R. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 2011, 29:7154-7162.
108. Monie A., Hung C.F., Roden R., Wu T.C. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008, 2:97-105.
109. Morrison T.G. Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens. Future Virol. 2010, 5:545-554.
110. Murata K., Lechmann M., Qiao M., Gunji T., Alter H.J., Liang T.J. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6753-6758.
111. Murawski M.R., McGinnes L.W., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., Heaton P.M., Fraire A.E., Morrison T.G. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J. Virol. 2010, 84:1110-1123.
112. Nagesha H.S., Wang L.F., Hyatt A.D., Morrissy C.J., Lenghaus C., Westbury H.A. Self-assembly, antigenicity, and immunogenicity of the rabbit haemorrhagic disease virus (Czechoslovakian strain V-351) capsid protein expressed in baculovirus. Arch. Virol. 1995, 140:1095-1108.
113. Nasir L., Campo M.S. Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. Vet. Dermatol. 2008, 19:243-254.
114. Naslund J., Lagerqvist N., Habjan M., Lundkvist A., Evander M., Ahlm C., Weber F., Bucht G. Vaccination with virus-like particles protects mice from lethal infection of Rift valley fever virus. Virology 2009, 385:409-415.
115. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 1999, 5:1157-1163.
116. Nicholas B.L., Brennan F.R., Martinez-Torrecuadrada J.L., Casal J.I., Hamilton W.D., Wakelin D. Characterization of the immune response to canine parvovirus induced by vaccination with chimaeric plant viruses. Vaccine 2002, 20:2727-2734.
117. Niedbalski W. Bluetongue vaccines in Europe. Pol. J. Vet. Sci. 2011, 14:299-304.
118. Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003, 11:438-444.
119. Paliard X., Liu Y., Wagner R., Wolf H., Baenziger J., Walker C.M. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses 2000, 16:273-282.
120. Pan Q., He K., Huang K. Development of recombinant porcine parvovirus-like particles as an antigen carrier formed by the hybrid VP2 protein carrying immunoreactive epitope of porcine circovirus type 2. Vaccine 2008, 26:2119-2126.
121. Peacey M., Wilson S., Baird M.A., Ward V.K. Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation. Biotechnol. Bioeng. 2007, 98:968-977.
122. Peacey M., Wilson S., Perret R., Ronchese F., Ward V.K., Young V., Young S.L., Baird M.A. Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response. Vaccine 2008, 26:5334-5337.
123. Perez-Filgueira D.M., Resino-Talavan P., Cubillos C., Angulo I., Barderas M.G., Barcena J., Escribano J.M. Development of a low-cost, insect larvae-derived recombinant subunit vaccine against RHDV. Virology 2007, 364:422-430.
124. Phelps J.P., Dang N., Rasochova L. Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis. J. Virol. Methods 2007, 141:146-153.
125. Pircher H., Moskophidis D., Rohrer U., Burki K., Hengartner H., Zinkernagel R.M. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 1990, 346:629-633.
126. Plana-Duran J., Bastons M., Rodriguez M.J., Climent I., Cortes E., Vela C., Casal I. Oral immunization of rabbits with VP60 particles confers protection against rabbit hemorrhagic disease. Arch. Virol. 1996, 141:1423-1436.
127. Plummer E.M., Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2011, 3:174-196.
128. Pope C.R. Chicken anemia agent. Vet. Immunol. Immunopathol. 1991, 30:51-65.
129. Raja K.S., Wang Q., Gonzalez M.J., Manchester M., Johnson J.E., Finn M.G. Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 2003, 4:472-476.
130. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev. Vaccines 2010, 9:1149-1176.
131. Roldao A., Silva A.C., Mellado M.C.M., Alves P.M., Carrondo M.J.T. Viruses and virus-like particles in biotechnology: fundamentals and applications. Comprehensive Biotechnology. Volume 1: Scientific Fundamentals in Biotechnology 2011, 625-649. Elsevier/Pergamon, Oxford, UK. 2nd edition. M. Moo-Young (Ed.).
132. Roy P., French T., Erasmus B.J. Protective efficacy of virus-like particles for bluetongue disease. Vaccine 1992, 10:28-32.
133. Roy P., Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum. Vaccin. 2008, 4:5-12.
134. Roy P., Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Adv. Exp. Med. Biol. 2009, 655:145-158.
135. Roy P., Urakawa T., Van Dijk A.A., Erasmus B.J. Recombinant virus vaccine for bluetongue disease in sheep. J. Virol. 1990, 64:1998-2003.
136. Rueda P., Fominaya J., Langeveld J.P., Bruschke C., Vela C., Casal J.I. Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine 2000, 19:726-734.
137. Ruedl C., Schwarz K., Jegerlehner A., Storni T., Manolova V., Bachmann M.F. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J. Virol. 2005, 79:717-724.
138. Rybicki E.P. Plant-produced vaccines: promise and reality. Drug Discov. Today 2009, 14:16-24.
139. Sainsbury F., Canizares M.C., Lomonossoff G.P. Cowpea mosaic virus: the plant virus-based biotechnology workhorse. Annu. Rev. Phytopathol. 2010, 48:437-455.
140. Saliki J.T., Mizak B., Flore H.P., Gettig R.R., Burand J.P., Carmichael L.E., Wood H.A., Parrish C.R. Canine parvovirus empty capsids produced by expression in a baculovirus vector: use in analysis of viral properties and immunization of dogs. J. Gen. Virol. 1992, 73(Pt 2):369-374.
141. Saunders K., Sainsbury F., Lomonossoff G.P. Efficient generation of cowpea mosaic virus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants. Virology 2009, 393:329-337.
142. Scheerlinck J.P., Greenwood D.L. Particulate delivery systems for animal vaccines. Methods 2006, 40:118-124.
143. Schirmbeck R., Bohm W., Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 1996, 39:111-119.
144. Sedlik C., Saron M., Sarraseca J., Casal I., Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:7503-7508.
145. Segales J., Domingo M. Postweaning multisystemic wasting syndrome (PMWS) in pigs: a review. Vet. Q. 2002, 24:109-124.
146. Shi L., Sings H.L., Bryan J.T., Wang B., Wang Y., Mach H., Kosinski M., Washabaugh M.W., Sitrin R., Barr E. GARDASIL: prophylactic human papillomavirus vaccine development-from bench top to bed-side. Clin. Pharmacol. Ther. 2007, 81:259-264.
147. Souza M., Costantini V., Azevedo M.S., Saif L.J. A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine 2007, 25:8448-8459.
148. Spohn G., Bachmann M.F. Exploiting viral properties for the rational design of modern vaccines. Expert Rev. Vaccines 2008, 7:43-54.
149. Stephenne J. Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness. Vaccine 1988, 6:299-303.
150. Storni T., Lechner F., Erdmann I., Bachi T., Jegerlehner A., Dumrese T., Kundig T.M., Ruedl C., Bachmann M.F. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J. Immunol. 2002, 168:2880-2886.
151. Strable E., Finn M.G. Chemical modification of viruses and virus-like particles. Curr. Top. Microbiol. Immunol. 2009, 327:1-21.
152. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., Newsome J.A., Jenson A.B., Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:11553-11557.
153. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S., Estes M.K. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 2003, 108:241-247.
154. Thiery R., Cozien J., Cabon J., Lamour F., Baud M., Schneemann A. Induction of a protective immune response against viral nervous necrosis in the European sea bass Dicentrarchus labrax by using betanodavirus virus-like particles. J. Virol. 2006, 80:10201-10207.
155. Tissot A.C., Renhofa R., Schmitz N., Cielens I., Meijerink E., Ose V., Jennings G.T., Saudan P., Pumpens P., Bachmann M.F. Versatile virus-like particle carrier for epitope based vaccines. PLoS ONE 2010, 5:e9809.
156. van Oers M.M. Opportunities and challenges for the baculovirus expression system. J. Invertebr. Pathol. 2011, 107(Suppl.):S3-S15.
157. Vicente T., Mota J.P.B., Peixoto C., Alves P.M., Carrondo M.J.T. Rational design and optimization of downstream processes of virus particles for biopharmaceutical applications: current advances. Biotechnol. Adv. 2011, 29:869-878.
158. Vicente T., Roldao A., Peixoto C., Carrondo M.J., Alves P.M. Large-scale production and purification of VLP-based vaccines. J. Invertebr. Pathol. 2011, 107(Suppl.):S42-S48.
159. Vitour D., Guillotin J., Sailleau C., Viarouge C., Desprat A., Wolff F., Belbis G., Durand B., Bakkali-Kassimi L., Breard E., Zientara S., Zanella G. Colostral antibody induced interference of inactivated bluetongue serotype-8 vaccines in calves. Vet. Res. 2011, 42:18.
160. Wang Q.H., Han M.G., Cheetham S., Souza M., Funk J.A., Saif L.J. Porcine noroviruses related to human noroviruses. Emerg. Infect. Dis. 2005, 11:1874-1881.
161. Warfield K.L., Aman M.J. Advances in virus-like particle vaccines for filoviruses. J. Infect. Dis. 2011, 204(Suppl. 3):S1053-S1059.
162. Wilschut J. Influenza vaccines: the virosome concept. Immunol. Lett. 2009, 122:118-121.
163. Wu L., Jiang L., Zhou Z., Fan J., Zhang Q., Zhu H., Han Q., Xu Z. Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector. Vaccine 2003, 21:4390-4398.
164. Xiang S.D., Scholzen A., Minigo G., David C., Apostolopoulos V., Mottram P.L., Plebanski M. Pathogen recognition and development of particulate vaccines: does size matter?. Methods 2006, 40:1-9.
165. Yan M., Peng J., Jabbar I.A., Liu X., Filgueira L., Frazer I.H., Thomas R. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology 2004, 324:297-310.
166. Yuan L., Geyer A., Hodgins D.C., Fan Z., Qian Y., Chang K.O., Crawford S.E., Parreno V., Ward L.A., Estes M.K., Conner M.E., Saif L.J. Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J. Virol. 2000, 74:8843-8853.
167. Yusibov V., Rabindran S., Commandeur U., Twyman R.M., Fischer R. The potential of plant virus vectors for vaccine production. Drugs R. D. 2006, 7(4):203-217.